MKK7 ASO suppresses the arthritis severity in K/BxN serum transfer arthritis. K/BxN serum was injected on Day 0 and PBS, control or MKK7 ASO (50 mg/kg) were injected i.v. twice a week from Day -8. Arthritis severity was determined with semi-quantitative clinical scoring and change in ankle thickness. Values = Mean ± SE, n = 7 to 8 mice for each group,*P < 0.05, **P < 0.01 vs. control ASO.